Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FBRX - Forte Biosciences Inc


IEX Last Trade
7.93
0.130   1.639%

Share volume: 19,484
Last Updated: Fri 30 Aug 2024 09:00:28 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$7.80
0.13
1.67%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
28%
Profitability 25%
Dept financing 11%
Liquidity 75%
Performance 24%
Company vs Stock growth
vs
Performance
5 Days
-0.19%
1 Month
-41.48%
3 Months
-49.44%
6 Months
-56.11%
1 Year
-61.56%
2 Year
-75.88%
Key data
Stock price
$7.93
P/E Ratio 
-4.75
DAY RANGE
N/A - N/A
EPS 
-$13.46
52 WEEK RANGE
$6.99 - $22.87
52 WEEK CHANGE
-$0.62
MARKET CAP 
288.381 M
YIELD 
N/A
SHARES OUTSTANDING 
36.504 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
-0.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$13,608
AVERAGE 30 VOLUME 
$9,656
Company detail
CEO: Martin Duvall
Region: US
Website: https://tocagen.com
Employees: 19
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

we are driven by a vision to end cancer mortality. our company was founded on this vision in 2007. tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. at the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (rrvs), which are designed to selectively deliver therapeutic genes into the dna of cancer cells. our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. in other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ he

Recent news